You’re so silly.
Go back and read the phase 2 small cohort readouts and decide for yourself that this is a treatment that shows a small improvement on top of current standard treatment. This is a high risk drug which marginally improves the patients condition, thus the “may” in the companies statement.
The market has spoken so don’t point the finger at me!
Anyway I’m always happy to be corrected, as I’d like to be a believer too!
Ann: Dimerix Completes $20M Placement, page-63
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
64.5¢ |
Change
0.065(11.2%) |
Mkt cap ! $354.5M | |||
| Open | High | Low | Value | Volume |
| 59.0¢ | 65.0¢ | 58.0¢ | $3.696M | 5.951M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100000 | 64.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 65.0¢ | 109360 | 4 |
View Market Depth
| Last trade - 16.10pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
64.5¢ |
Change
0.065 ( 12.4 %) |
||||
| Open | High | Low | Volume | ||
| 59.0¢ | 65.5¢ | 58.5¢ | 3782284 | ||
| Last updated 15.59pm 14/06/2024 ? | |||||
| DXB (ASX) Chart |